{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:28:31Z","timestamp":1792859311209,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bioorg.2021.105149","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T02:48:40Z","timestamp":1625626120000},"page":"105149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer\u2019s disease agents"],"prefix":"10.1016","volume":"114","author":[{"given":"Hongwei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105149_b0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2021.105149_b0010","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/291214","article-title":"Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening","author":"Gupta","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bioorg.2021.105149_b0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/08927022.2014.910600","article-title":"Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (A beta) peptide aggregation for treating Alzheimer\u2019s disease","volume":"41","author":"Zhou","year":"2015","journal-title":"Mol. Simul."},{"key":"10.1016\/j.bioorg.2021.105149_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.bioorg.2021.105149_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","article-title":"Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer\u2019s disease","volume":"33","author":"Leon","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2021.105149_b0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","article-title":"A review on cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"36","author":"Anand","year":"2013","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2021.105149_b0035","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1039\/C6RA25887E","article-title":"Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening","volume":"7","author":"Chen","year":"2017","journal-title":"Rsc Adv."},{"key":"10.1016\/j.bioorg.2021.105149_b0040","article-title":"Evaluation of novel dual Acetyl- and Butyrylcholinesterase inhibitors as potential anti-alzheimer\u2019s disease agents using pharmacophore, 3D-QSAR, and molecular docking approaches","volume":"22","author":"Pang","year":"2017","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.bioorg.2021.105149_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1752-153X-7-116","article-title":"Acetyl and butyryl cholinesterase inhibitory sesquiterpene lactones from Amberboa ramosa","volume":"7","author":"Ibrahim","year":"2013","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.bioorg.2021.105149_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1479-7364-4-2-91","article-title":"Cholinesterase inhibitors in Alzheimer\u2019s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story","volume":"4","author":"Lam","year":"2009","journal-title":"Hum. Genom."},{"key":"10.1016\/j.bioorg.2021.105149_b0055","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4155\/fmc-2017-0036","article-title":"Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer\u2019s disease","volume":"9","author":"Knez","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105149_b0060","first-page":"1","article-title":"Acetylcholinesterase enzyme inhibitor activity of some novel pyrazinamide condensed 1,2,3,4-tetrahydropyrimidines","volume":"5","author":"Elumalai","year":"2015","journal-title":"Biotechnol. Rep. Amst. Neth."},{"key":"10.1016\/j.bioorg.2021.105149_b0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/jnnp.67.4.558","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress - Reply","volume":"67","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/j.bioorg.2021.105149_b0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/cbdd.12825","article-title":"Computer-aided drug design to explore cyclodextrin therapeutics and biomedical applications","volume":"89","author":"Abdolmaleki","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2021.105149_b0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bioorg.2017.12.015","article-title":"Pharmacophore-based drug design for potential AChE inhibitors from Traditional Chinese Medicine Database","volume":"76","author":"Jiang","year":"2018","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.bioorg.2021.105149_b0080","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: challenges and recent advances","volume":"15","author":"Yang","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2021.105149_b0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1423-0127-18-8","article-title":"The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies","volume":"18","author":"Lu","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2021.105149_b0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jmgm.2007.07.002","article-title":"Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads","volume":"26","author":"Vadivelan","year":"2008","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2021.105149_b0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jmgm.2012.12.008","article-title":"Identification of potential bivalent inhibitors from natural compounds for acetylcholinesterase through in silico screening using multiple pharmacophores","volume":"40","author":"Lakshmi","year":"2013","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2021.105149_b0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biosystems.2013.12.002","article-title":"Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer\u2019s agents","volume":"116","author":"Ambure","year":"2014","journal-title":"Biosystems"},{"key":"10.1016\/j.bioorg.2021.105149_b0105","series-title":"Discovery Studio modeling environment, Release 2016","author":"Dassault Syst\u00e8mes BIOVIA","year":"2015"},{"key":"10.1016\/j.bioorg.2021.105149_b0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.phymed.2018.09.199","article-title":"Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer\u2019s disease","volume":"54","author":"Jiang","year":"2019","journal-title":"Phytomedicine."},{"key":"10.1016\/j.bioorg.2021.105149_b0115","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jmgm.2017.07.020","article-title":"Pharmacophore based design of some multi-targeted compounds targeted against pathways of diabetic complications","volume":"76","author":"Chadha","year":"2017","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2021.105149_b0120","doi-asserted-by":"crossref","unstructured":"J. Sopkova-de Oliveira Santos, A. Lesnard, J.-H. Agondanou, N. Dupont, A.-M. Godard, S. Stiebing, C. Rochais, F. Fabis, P. Dallemagne, R. Bureau, S. Rault, Virtual screening discovery of new Acetylcholinesterase inhibitors issued from CERMN Chemical Library, J. Chem. Inf. Model. 50 (2010) 422\u2013428.","DOI":"10.1021\/ci900491t"},{"key":"10.1016\/j.bioorg.2021.105149_b0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2021.105149_b0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17425250902902322","article-title":"ADME pharmacogenetics: current practices and future outlook","volume":"5","author":"Grossman","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bioorg.2021.105149_b0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1359-6446(01)02100-6","article-title":"The emerging importance of predictive ADME simulation in drug discovery","volume":"7","author":"Beresford","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2021.105149_b0140","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1021\/jm501195e","article-title":"Discovery, biological evaluation, and crystal structure of a novel nanomolar selective Butyrylcholinesterase inhibitor","volume":"57","author":"Brus","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105149_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopha.2016.02.020","article-title":"Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking","volume":"80","author":"Thiyagarajan","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2021.105149_b0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1023\/A:1014224900524","article-title":"Experimental and computational screening models for prediction of aqueous drug solubility","volume":"19","author":"Bergstrom","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2021.105149_b0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bioorg.2021.105149_b0160","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1016\/j.bmc.2010.08.003","article-title":"QSAR-based solubility model for drug-like compounds","volume":"18","author":"Gozalbes","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105149_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5173(00)00422-1","article-title":"A simple model for the prediction of blood-brain partitioning","volume":"201","author":"Feher","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2021.105149_b0170","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/jm990968+","article-title":"Predicting blood-brain barrier permeation from three-dimensional molecular structure","volume":"43","author":"Crivori","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105149_b0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bioorg.2017.09.004","article-title":"Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer\u2019s disease: a review","volume":"75","author":"Jiang","year":"2017","journal-title":"Bioorganic Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821005265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821005265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:31:18Z","timestamp":1758616278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821005265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"alternative-id":["S0045206821005265"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105149","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer\u2019s disease agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105149"}}